JFL Life Sciences Ltd
JFL Life Sciences Q2 Results 2026 (FY27) statement: Revenue & Margins
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
JFL Life Sciences Ltd Q2 FY27 key numbers
- Revenue
- Revenue from operations for the quarter ended 30th September 2026 was Rs. 586.45 lakhs.
As stated in JFL Life Sciences Ltd's Q2 FY27 results statement · published 2 Nov 2026. Reported figures, not investment advice.
Based on JFL Life Sciences Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Revenue from operations for the quarter ended 30th September 2026 was Rs. EBITDA for the quarter ended 30 September 2026: Rs.
From JFL Life Sciences Ltd's Q2 FY27 earnings-call transcript · updated 2 Nov 2026.
Revenue & Sales Performance
- Revenue from operations for the quarter ended 30th September 2026 was Rs. 586.45 lakhs.
- Revenue for the same quarter in the previous year (30th September 2025) was Rs. 299.07 lakhs.
- This represents a year-on-year increase of approximately 96% in revenue for the quarter.
Profitability & Margins
See what JFL Life Sciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
See what JFL Life Sciences Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what JFL Life Sciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what JFL Life Sciences Ltd said on order book & pipeline — free account, 30 seconds.
JFL Life Sciences Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Jun 2026 (Q1 FY27). The Q2 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹11 Cr, net profit ₹1 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
Others in Pharmaceuticals & Biotechnology this season
- Wockhardt Ltd (Q2 FY27)
969 crore, up from Rs. Key results statement takeaways from Wockhardt Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- P & G Health Ltd (Q2 FY27)
Revenue from Operations for the quarter ended September 30, 2026, is ₹38,249 lakhs (Page 4). Key results statement takeaways from Procter & Gamble Health Ltd's
- Akums Drugs (Q2 FY27)
Q2 FY27 revenue reported at ₹1,342 crore, up 31.9% YoY from ₹1,018 crore in Q2 FY26 (Page 12, 10). Key investor presentation takeaways from Akums Drugs & Pharma
- Sai Parenteral's (Q2 FY27)
Q2FY27 Revenue from Operations: ₹196.1 crore, up 257.4% YoY from ₹54.9 crore in Q2FY26 (Page 56). Key investor presentation takeaways from Sai Parenterals Ltd's
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
JFL Life Sciences Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were JFL Life Sciences Ltd Q2 FY27 results?
Revenue from operations for the quarter ended 30th September 2026 was Rs. EBITDA for the quarter ended 30 September 2026: Rs.
What is JFL Life Sciences Ltd share price analysis?
JFL Life Sciences Ltd currently shows a neutral. The stock trades at a P/E of 5.0 with a market cap of ₹34 Cr. Investors should review the full earnings analysis for detailed insights.
Keep JFL Life Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.